Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations
BackgroundThe combination of amivantamab and lazertinib has demonstrated clinically significant and sustained antitumor effects in both treatment-naïve and osimertinib-pretreated advanced non-small cell lung cancer (NSCLC) patients harboring previously untreated epidermal growth factor receptor (EGF...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2025-05-01
|
| סדרה: | Frontiers in Pharmacology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1527614/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|